glp 1 gastric issues GLP-1 Agonists For Obesity In Non-Diabetic Patients: Game Changer Or Overhyped? A Critical Analysis GlobalRPH The promise and peril of
Description
Efficacy and safety of the novel triple agonist retatrutide in type 2 diabetes. NEJM , 2023
Fatigue Vomiting Nausea Diarrhea Dizziness Headache Reduced tolerance to exercise Insomnia Muscle cramps Skin rash Why Does Ketosis Make Urine Smell
Central and peripheral GLP1 systems independently suppress eating
Oxidative stress in arthritis
Interestingly, some reports suggest retatrutide's balanced receptor activation may produce fewer GI issues than equivalent weight loss from single agonists, though this requires further investigation
